Published in Fitness and Wellness Business Week, June 28th, 2006
This agreement provides for development of needle-free injection devices in the fields of diabetes and obesity. The filing incorporates development work focused on making products more patient friendly related to the Antares' core needle-free injector technology. This work could enhance the needle-free technology that Antares already sells into the U.S. insulin market as the MediJector Vision.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Fitness and Wellness Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.